Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not
Otto Hemminki(University of Helsinki), Akseli Hemminki(University of Helsinki), Johan Björklund(Karolinska University Hospital), Alexandre R. Zlotta(University of Toronto), Nathan Perlis(University of Toronto), Antonio Finelli(University Health Network)
Cited by 15
Related Papers
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus
|Molecular Therapy|2003|172
Daclizumab phase II trial in relapsing and remitting multiple sclerosis
|Neurology|2007|161